• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

研究 GalNAc-siRNA 缀合物的药效持久性。

Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.

机构信息

Alnylam Pharmaceuticals, Inc., Cambridge, MA 02142, USA.

MGH Program in Membrane Biology, Division of Nephrology, Massachusetts General Hospital and Harvard Medical School, Boston, MA 02114, USA.

出版信息

Nucleic Acids Res. 2020 Dec 2;48(21):11827-11844. doi: 10.1093/nar/gkaa670.

DOI:10.1093/nar/gkaa670
PMID:32808038
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7708070/
Abstract

One hallmark of trivalent N-acetylgalactosamine (GalNAc)-conjugated siRNAs is the remarkable durability of silencing that can persist for months in preclinical species and humans. Here, we investigated the underlying biology supporting this extended duration of pharmacological activity. We found that siRNA accumulation and stability in acidic intracellular compartments is critical for long-term activity. We show that functional siRNA can be liberated from these compartments and loaded into newly generated Argonaute 2 protein complexes weeks after dosing, enabling continuous RNAi activity over time. Identical siRNAs delivered in lipid nanoparticles or as GalNAc conjugates were dose-adjusted to achieve similar knockdown, but only GalNAc-siRNAs supported an extended duration of activity, illustrating the importance of receptor-mediated siRNA trafficking in the process. Taken together, we provide several lines of evidence that acidic intracellular compartments serve as a long-term depot for GalNAc-siRNA conjugates and are the major contributor to the extended duration of activity observed in vivo.

摘要

三价 N-乙酰半乳糖胺(GalNAc)缀合的 siRNA 的一个显著特点是沉默作用的持久性,可以在临床前物种和人类中持续数月。在这里,我们研究了支持这种延长的药理活性的基础生物学。我们发现,siRNA 在酸性细胞内隔室中的积累和稳定性对于长期活性至关重要。我们表明,功能性 siRNA 可以从这些隔室中释放出来,并在给药数周后加载到新生成的 Argonaute 2 蛋白复合物中,从而随着时间的推移持续进行 RNAi 活性。在脂质纳米颗粒或 GalNAc 缀合物中递送相同的 siRNA 以实现类似的敲低,但只有 GalNAc-siRNA 支持延长的活性持续时间,这说明了受体介导的 siRNA 转运在该过程中的重要性。综上所述,我们提供了几条证据表明,酸性细胞内隔室充当 GalNAc-siRNA 缀合物的长期储存库,是体内观察到的延长活性持续时间的主要贡献者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/bf5c5a2b90a8/gkaa670fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/7190fd8a7171/gkaa670fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/c32726effcf4/gkaa670fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/2efc6032e6b4/gkaa670fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/86a13ac215e2/gkaa670fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/5993103af884/gkaa670fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/993d3423e62d/gkaa670fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/a3907292b576/gkaa670fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/3c1e46a72d0b/gkaa670fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/e28c3653407e/gkaa670fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/e10cd49f4094/gkaa670fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/bf5c5a2b90a8/gkaa670fig10.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/7190fd8a7171/gkaa670fig11.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/c32726effcf4/gkaa670fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/2efc6032e6b4/gkaa670fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/86a13ac215e2/gkaa670fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/5993103af884/gkaa670fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/993d3423e62d/gkaa670fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/a3907292b576/gkaa670fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/3c1e46a72d0b/gkaa670fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/e28c3653407e/gkaa670fig8.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/e10cd49f4094/gkaa670fig9.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/889b/7708070/bf5c5a2b90a8/gkaa670fig10.jpg

相似文献

1
Investigating the pharmacodynamic durability of GalNAc-siRNA conjugates.研究 GalNAc-siRNA 缀合物的药效持久性。
Nucleic Acids Res. 2020 Dec 2;48(21):11827-11844. doi: 10.1093/nar/gkaa670.
2
Hepatocyte-specific delivery of siRNAs conjugated to novel non-nucleosidic trivalent N-acetylgalactosamine elicits robust gene silencing in vivo.与新型非核苷三价N-乙酰半乳糖胺偶联的小干扰RNA(siRNA)的肝细胞特异性递送在体内引发了强大的基因沉默。
Chembiochem. 2015 Apr 13;16(6):903-8. doi: 10.1002/cbic.201500023. Epub 2015 Mar 18.
3
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.半乳糖胺-siRNA 偶联物:引领 RNAi 治疗药物递送的前沿。
Nucleic Acid Ther. 2018 Jun;28(3):109-118. doi: 10.1089/nat.2018.0736. Epub 2018 May 24.
4
Evaluation of GalNAc-siRNA Conjugate Activity in Pre-clinical Animal Models with Reduced Asialoglycoprotein Receptor Expression.GalNAc-siRNA 缀合物在表达降低的去唾液酸糖蛋白受体的临床前动物模型中的活性评估。
Mol Ther. 2018 Jan 3;26(1):105-114. doi: 10.1016/j.ymthe.2017.08.019. Epub 2017 Sep 7.
5
siRNA conjugates carrying sequentially assembled trivalent N-acetylgalactosamine linked through nucleosides elicit robust gene silencing in vivo in hepatocytes.通过核苷连接的顺序组装三价N-乙酰半乳糖胺的小干扰RNA缀合物在体内肝细胞中引发强大的基因沉默。
ACS Chem Biol. 2015 May 15;10(5):1181-7. doi: 10.1021/cb501028c. Epub 2015 Mar 2.
6
Clinical Proof of Concept for a Novel Hepatocyte-Targeting GalNAc-siRNA Conjugate.新型靶向肝细胞的GalNAc-siRNA偶联物的临床概念验证
Mol Ther. 2017 Jan 4;25(1):71-78. doi: 10.1016/j.ymthe.2016.10.019.
7
Impact of Serum Proteins on the Uptake and RNAi Activity of GalNAc-Conjugated siRNAs.血清蛋白对 GalNAc 缀合 siRNA 的摄取和 RNAi 活性的影响。
Nucleic Acid Ther. 2021 Aug;31(4):309-315. doi: 10.1089/nat.2020.0919. Epub 2021 Apr 15.
8
Minimal Physiologically Based Pharmacokinetic-Pharmacodynamic (mPBPK-PD) Model of -Acetylgalactosamine-Conjugated Small Interfering RNA Disposition and Gene Silencing in Preclinical Species and Humans.基于生理的最小药效动力学(mPBPK-PD)模型:-乙酰半乳糖胺缀合的小干扰 RNA 在临床前物种和人体中的处置和基因沉默。
J Pharmacol Exp Ther. 2021 Nov;379(2):134-146. doi: 10.1124/jpet.121.000805. Epub 2021 Aug 19.
9
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.GalNAc-siRNA 缀合物的高级 siRNA 设计可进一步改善体内性能。
Mol Ther. 2018 Mar 7;26(3):708-717. doi: 10.1016/j.ymthe.2017.12.021. Epub 2018 Jan 4.
10
Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing.多价 N-乙酰半乳糖胺修饰的 siRNA 定位于肝细胞并引发强烈的 RNAi 介导的基因沉默。
J Am Chem Soc. 2014 Dec 10;136(49):16958-61. doi: 10.1021/ja505986a. Epub 2014 Dec 1.

引用本文的文献

1
RNA Therapeutics: Bridging Discovery and Clinical Implementation.RNA疗法:连接发现与临床应用
Methods Mol Biol. 2025;2965:1-37. doi: 10.1007/978-1-0716-4742-4_1.
2
Improving the Cellular Accumulation of Folate-Conjugated Fully Chemically Modified siRNAs via 3' Terminal Conjugation.通过3'末端共轭提高叶酸共轭的完全化学修饰小干扰RNA的细胞积累
ACS Omega. 2025 Jul 25;10(30):32744-32753. doi: 10.1021/acsomega.4c11519. eCollection 2025 Aug 5.
3
Realizing the therapeutic potential of rapid knockdown of transthyretin via RNA interference in transthyretin amyloidosis.

本文引用的文献

1
Phase 3 Trial of RNAi Therapeutic Givosiran for Acute Intermittent Porphyria.急性间歇性卟啉症的 RNAi 治疗药物 Givosiran 的 3 期临床试验。
N Engl J Med. 2020 Jun 11;382(24):2289-2301. doi: 10.1056/NEJMoa1913147.
2
RT-qPCR Methods to Support Pharmacokinetics and Drug Mechanism of Action to Advance Development of RNAi Therapeutics.用于支持 RNAi 治疗药物药代动力学和作用机制的 RT-qPCR 方法,以推进其研发。
Nucleic Acid Ther. 2020 Jun;30(3):133-142. doi: 10.1089/nat.2019.0840. Epub 2020 Mar 23.
3
Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol.
通过RNA干扰快速敲低转甲状腺素蛋白在转甲状腺素蛋白淀粉样变性中的治疗潜力。
Mol Ther Nucleic Acids. 2025 Jun 10;36(3):102590. doi: 10.1016/j.omtn.2025.102590. eCollection 2025 Sep 9.
4
Elucidating brain transport pathways and cell type-dependent gene silencing of a durable lipid-siRNA conjugate administered into cerebrospinal fluid.阐明经脑脊液注射的持久脂质-小干扰RNA偶联物的脑转运途径及细胞类型依赖性基因沉默。
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf600.
5
Inhibition of Factor XI Using RBD4059: A Novel GalNAc-siRNA With Potent and Durable Antithrombotic Effects.使用RBD4059抑制凝血因子XI:一种具有强效和持久抗血栓作用的新型GalNAc-siRNA
JACC Basic Transl Sci. 2025 Jun;10(6):786-797. doi: 10.1016/j.jacbts.2024.12.005. Epub 2025 Feb 19.
6
Systematic analysis of siRNA and mRNA features impacting fully chemically modified siRNA efficacy.影响完全化学修饰的小干扰RNA(siRNA)功效的siRNA和信使核糖核酸(mRNA)特征的系统分析
Nucleic Acids Res. 2025 Jun 20;53(12). doi: 10.1093/nar/gkaf479.
7
A first-in-class EGFR-directed KRAS G12V selective inhibitor.一种一流的表皮生长因子受体导向的KRAS G12V选择性抑制剂。
Cancer Cell. 2025 Jun 16. doi: 10.1016/j.ccell.2025.05.016.
8
Cross-species translational modelling of targeted therapeutic oligonucleotides using physiologically based pharmacokinetics.使用基于生理学的药代动力学对靶向治疗性寡核苷酸进行跨物种翻译建模。
J Pharmacokinet Pharmacodyn. 2025 Jun 12;52(4):35. doi: 10.1007/s10928-025-09980-9.
9
Multimeric Conjugates Using Engineered Peptide Scaffolds for Efficient siRNA Delivery.利用工程化肽支架的多聚体偶联物实现高效的小干扰RNA递送
Bioconjug Chem. 2025 Jun 18;36(6):1299-1310. doi: 10.1021/acs.bioconjchem.5c00156. Epub 2025 May 29.
10
Dissolving microneedles for nucleic acid delivery: A systematic search, review, and data synthesis.用于核酸递送的可溶解微针:系统检索、综述与数据综合
Acta Biomater. 2025 Jun 15;200:115-131. doi: 10.1016/j.actbio.2025.05.025. Epub 2025 May 9.
两项降低 LDL 胆固醇的依洛尤单抗 3 期临床试验。
N Engl J Med. 2020 Apr 16;382(16):1507-1519. doi: 10.1056/NEJMoa1912387. Epub 2020 Mar 18.
4
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs.Onpattro的故事以及含核酸类药物的纳米药物的临床转化。
Nat Nanotechnol. 2019 Dec;14(12):1084-1087. doi: 10.1038/s41565-019-0591-y.
5
GalNAc-siRNA Conjugates: Leading the Way for Delivery of RNAi Therapeutics.半乳糖胺-siRNA 偶联物:引领 RNAi 治疗药物递送的前沿。
Nucleic Acid Ther. 2018 Jun;28(3):109-118. doi: 10.1089/nat.2018.0736. Epub 2018 May 24.
6
RNA Therapeutics (Almost) Comes of Age: Targeting, Delivery and Endosomal Escape.RNA疗法(几乎)走向成熟:靶向、递送与内体逃逸
Nucleic Acid Ther. 2018 Jun;28(3):107-108. doi: 10.1089/nat.2018.29001.dow. Epub 2018 May 21.
7
Intracellular Trafficking and Endosomal Release of Oligonucleotides: What We Know and What We Don't.寡核苷酸的细胞内转运和内体释放:已知与未知。
Nucleic Acid Ther. 2018 Jun;28(3):166-177. doi: 10.1089/nat.2018.0727. Epub 2018 Apr 30.
8
Advanced siRNA Designs Further Improve In Vivo Performance of GalNAc-siRNA Conjugates.GalNAc-siRNA 缀合物的高级 siRNA 设计可进一步改善体内性能。
Mol Ther. 2018 Mar 7;26(3):708-717. doi: 10.1016/j.ymthe.2017.12.021. Epub 2018 Jan 4.
9
Facile Synthesis, Geometry, and 2'-Substituent-Dependent in Vivo Activity of 5'-(E)- and 5'-(Z)-Vinylphosphonate-Modified siRNA Conjugates.5'-(E)-和 5'-(Z)-乙烯基膦酸酯修饰的 siRNA 缀合物的简便合成、几何形状和 2'-取代基依赖性体内活性。
J Med Chem. 2018 Feb 8;61(3):734-744. doi: 10.1021/acs.jmedchem.7b01147. Epub 2018 Jan 27.
10
Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.反义寡核苷酸和双链 RNA 的化学、机制和临床状况。
Nucleic Acids Res. 2018 Feb 28;46(4):1584-1600. doi: 10.1093/nar/gkx1239.